Every 8-K that Dynavax Technologies Corporation (DVAX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DVAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DVAX filings page.
Dynavax Technologies Corporation has completed its acquisition by Sanofi through a tender offer and follow‑on merger, cashing out each share of common stock for $15.50 in cash, without interest and subject to taxes. The tender offer expired on February 9, 2026, with 84,680,752 shares validly tendered, representing about 73.92% of outstanding shares, satisfying the minimum condition for closing.
Following the merger under Delaware law, Dynavax became an indirect wholly owned subsidiary of Sanofi, and the company requested that Nasdaq halt trading, delist the shares and file to deregister them. Convertible notes due 2026 and 2030 were amended so conversions now deliver cash based on the existing conversion rate multiplied by $15.50. Equity awards were largely cashed out at the merger price, with a portion of recent unvested grants converted into cash‑based awards that vest six months after closing, generally accelerating on involuntary termination.
The entire pre‑merger board resigned at closing and was replaced by Sanofi‑designated directors and officers. Certain senior executives received excise tax reimbursement protections on merger‑related payments, subject to individual caps.
Dynavax Technologies Corporation furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025 and unveiling a new $100 million share repurchase program via an accompanying press release. The press release was furnished as Exhibit 99.1 and provides the detailed results and program terms.
This 8-K indicates the results and buyback authorization were communicated through a press release that is incorporated by reference for informational purposes, while the 8-K itself notes the information is furnished, not filed under the Exchange Act. Shares of DVAX continue to trade on the Nasdaq Global Select Market.
Dynavax Technologies Corporation announced leadership changes tied to an internal realignment. Effective January 1, 2026, David F. Novack will transition from President and Chief Operating Officer to Senior Vice President and Chief Operating Officer.
The Board approved the removal of Robert Janssen, M.D. from his roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, effective upon the earlier of the Company hiring a new Chief Medical Officer or March 2, 2026. Dr. Janssen’s employment will conclude as of March 2, 2026. The Company has commenced a search for a successor Chief Medical Officer.
Dynavax Technologies Corporation reported that it has released topline results from Part 1 of its Phase 1/2 clinical trial of Z-1018, its novel shingles vaccine candidate. The study is randomized, observer-blinded, and active-controlled, testing Z-1018 head-to-head against Shingrix in adults aged 50 to 69 years. Dynavax also updated its corporate presentation to include information on this Phase 1/2 trial, and both the press release and presentation are provided as exhibits to the report.